According to Alnylam Pharmaceuticals
's latest financial reports the company has $2.37 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $2.43 B | 11.27% |
2022-12-31 | $2.19 B | -9.98% |
2021-12-31 | $2.43 B | 29.94% |
2020-12-31 | $1.87 B | 22.02% |
2019-12-31 | $1.53 B | 41.69% |
2018-12-31 | $1.08 B | -35.87% |
2017-12-31 | $1.69 B | 169.72% |
2016-12-31 | $0.62 B | -41.99% |
2015-12-31 | $1.08 B | 55.09% |
2014-12-31 | $0.69 B | 183.36% |
2013-12-31 | $0.24 B | 100.2% |
2012-12-31 | $0.12 B | -16.11% |
2011-12-31 | $0.14 B | -37.2% |
2010-12-31 | $0.23 B | -17.15% |
2009-12-31 | $0.28 B | -34.62% |
2008-12-31 | $0.43 B | 10.37% |
2007-12-31 | $0.38 B | 79.48% |
2006-12-31 | $0.21 B | 171.57% |
2005-12-31 | $80 M | 73.74% |
2004-12-31 | $46.04 M | 98.53% |
2003-12-31 | $23.19 M | 49.85% |
2002-12-31 | $15.47 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Novartis NVS | $9.69 B | 308.81% | ๐จ๐ญ Switzerland |
Sanofi SNY | $9.92 B | 318.68% | ๐ซ๐ท France |
Regeneron Pharmaceuticals REGN | $10.51 B | 343.62% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | $1.39 B | -41.35% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | $23.76 M | -99.00% | ๐บ๐ธ USA |
OPKO Health
OPK | $95.88 M | -95.96% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | $3.22 B | 36.04% | ๐ฎ๐ฑ Israel |
Arrowhead Pharmaceuticals
ARWR | $0.22 B | -90.71% | ๐บ๐ธ USA |